http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102390931-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102390931-B1 |
| titleOfInvention | Novel polypeptide binding with human complement component 3a and usese thereof |
| abstract | The present invention relates to a novel polypeptide that selectively binds to the complement proteolysis product C3a, and more particularly, the present invention relates to a polypeptide capable of inhibiting its activity by binding to the human complement proteolysis product C3a, the polypeptide encoding the polypeptide It relates to a polynucleotide, a recombinant vector comprising the polynucleotide, a recombinant microorganism into which the recombinant vector is introduced, a method for producing the polypeptide using the recombinant microorganism, and a therapeutic pharmaceutical composition comprising the polypeptide. The novel polypeptide binding to the complement proteolysis product C3a of the present invention binds to the complement proteolysis product C3a with a higher affinity than the naturally occurring complement proteolysis product C3a receptor and inhibits its activity, thereby being associated with the complement proteolysis product C3a. It is useful because it can be widely used in the development of agents for the prevention or treatment of various diseases. |
| priorityDate | 2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 413.